P3‐345: MRI BRAIN IMAGE ENHANCEMENT USING CONTOURLET TRANSFORM ALONG WITH AN ENHANCEMENT FUNCTION

we observed that the reaction between pyrazole-aldehyde and difluoro-boronate-diketone was very rapid even under 60 C. Therefore, we designed CRANAD-101F, an analogue of half-curcumin and half-CRANAD-28. We installed a cyclobutyl ring to prevent possible double-labeling and reduce the tauromerization of the diketone, which can reduce the side reactions. As a result, we successfully synthesized the F18-labeled CRANAD-101F with a relatively high radiochemical yield (28%, no-decay corrected) through a one-pot two-step reaction at 80 C. Results: In vitro fluorescence studies indicated that CRANAD-101F was sensitive to various A}$^[fish 0,mfnt]>bs. In vivo PET imaging data indicated that its brain uptake (%ID/cc) in wild type mice at 2 min was about 3.0%, and the ratio of 2min/30min of brain signal was about 2.8, indicating that it had a moderate washout rate. PET imaging results indicated that transgenic 14-month APP/PS1 mice had higher signals in brain than the age-matched wild type mice (Fig.1). The differences were 1.54-, 1.59, 1.61-, and 1.69-folds at 5-, 18-, 30-, and 60-minutes post IV injection. Conclusions:Our in vitro and in vivo PET imaging data indicate that it is feasible to use half-curcuminoid scaffolds for developing PET tracers for AD. We believe that CRANAD-101F could be a potential PET imaging probe for positive diagnosis of Alzheimer’s disease.